NCT01101594 (Clinical Trial / hLL1-DOX / IMMU-110)

Study Title
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (NCT01101594)

Trial Description
This study is a Ph I trial to test the safety of the study drug, hLL1-DOX (also known as Milatuzumab-DOX, CD-74-DOX, hCD74-DOX and IMMU-110), at different dose levels in patients with recurrent multiple myeloma. HLL1 is also known as milatuzumab and is attached to doxorubicin in this clinical trial.

This trial is sponsored by Immunomedics Inc. [1]

Study Data

  • Condition: Multiple Myeloma
  • Interventions:
    • Drugs used in this trial
      • hLL1-DOX (Milatuzumab-DOX, IMMU-110, CD-74-DOX, hCD74-DOX)
  • Phase: I & II
  • Estimated Enrollment: 42
  • Start: July 2010
  • Completion: July 2013
  • Last verified: January 2014

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: Augus 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.